Xcovery is a biopharmaceutical company focusing on improving the lives of patients with cancer. Xcovery is currently developing a pipeline of drugs targeting a wide range of advanced solid tumors with a focus on lung cancer, including ensartinib, a next generation ALK inhibitor finishing up its global phase 3 registration trial in first-line treatment of ALK positive NSCLC.